ROSEMARY BROWN: Open Payments
NPI 1972504231 · REXBURG, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,767 in 53 payments from 10 companies in 2025. Trend: 2023 $1,431 · 2024 $1,448 · 2025 $1,767
Food & beverage: $1,656Education: $111
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $428 |
| Tris Pharma Inc | 4 | $274 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $262 |
| Teva Pharmaceuticals USA, Inc. | 7 | $198 |
| Alkermes, Inc. | 6 | $174 |
| Otsuka America Pharmaceutical, Inc. | 7 | $155 |
| Neurocrine BioSciences, Inc. | 7 | $151 |
| ABBVIE INC. | 4 | $85 |
| Corium, LLC | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: COBENFY, CAPLYTA, INGREZZA, Dyanavel XR, LYBALVI, REXULTI, VRAYLAR, AUSTEDO XR.
Industry payments across ID — which companies pay providers there.
